ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,741Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 143

$411K Total Retail Price of All Prescriptions

Rank: 39 out of 143

311 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
76% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Delaware
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

4% of this provider’s 311 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,077 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $79 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Delaware
AMLODIPINE BESYLATE 386 339 1 4
PRAVASTATIN SODIUM 377 313 2 9
LISINOPRIL 326 175 3 1
ZOLPIDEM TARTRATE 321 196 4 13
AMLODIPINE BESYLATE-BENAZEPRIL 297 213 5 84
OMEPRAZOLE 239 207 6 5
METFORMIN HCL 218 162 7 8
ATORVASTATIN CALCIUM 212 186 8 7
ALENDRONATE SODIUM 201 169 9 40
SIMVASTATIN 170 121 10 2
EVISTA 146 139 11 153
CLOPIDOGREL 137 112 12 33
FLOVENT HFA 128 72 13 160
VENTOLIN HFA 118 72 14 110
IBUPROFEN 115 71 15 117
LOSARTAN POTASSIUM 111 95 16 19
SINGULAIR 110 79 17 148
FUROSEMIDE 109 88 18 6
FLUTICASONE PROPIONATE 108 72 19 37
TAMSULOSIN HCL 107 72 20 28
NAPROXEN 104 97 21 81
NABUMETONE 104 78 21 171
METOPROLOL SUCCINATE 103 66 23 14
HYDROCHLOROTHIAZIDE 100 64 24 10
GABAPENTIN 99 28 25 18
JANUVIA 95 95 26 54
LEVOTHYROXINE SODIUM 95 52 26 3
DOXAZOSIN MESYLATE 93 61 28 91
FINASTERIDE 90 76 29 97
DICLOFENAC SODIUM 88 51 30 181
ATENOLOL 86 59 31 11
PLAVIX 84 72 32 51
TRAMADOL HCL 84 40 32 16
CYCLOBENZAPRINE HCL 79 12 R 34 77
RANITIDINE HCL 79 48 34 41
LISINOPRIL-HYDROCHLOROTHIAZIDE 76 61 36 21
PANTOPRAZOLE SODIUM 73 66 37 43
SERTRALINE HCL 72 28 38 23
GLYBURIDE 72 55 R 38 107
MONTELUKAST SODIUM 66 49 40 197
METOPROLOL TARTRATE 65 40 41 12
TRAMADOL HCL-ACETAMINOPHEN 61 25 42 136
NIFEDICAL XL 59 18 43 128
POTASSIUM CHLORIDE 58 40 44 34
GLYBURIDE-METFORMIN HCL 58 24 R 44 206
LACTULOSE 54 21 46 116
ISOSORBIDE MONONITRATE ER 51 20 47 44
DIOVAN 51 41 47 26
WARFARIN SODIUM 51 22 47 15
TRIAMTERENE-HCTZ 50 39 50 89
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 1, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.